John Stuelpnagel

John Stuelpnagel has been Chairman of Inscripta^® since 2017. He co-founded Illumina in 1997, becoming its first CEO, and later its COO. During his 12 years with Illumina, Dr. Stuelpnagel was a driving force behind the company’s transformation from a private start-up to the global leader in next-generation sequencing. 

After leaving Illumina in 2009, Dr. Stuelpnagel co-founded Ariosa Diagnostics, where he also served as Executive Chairman until the company’s acquisition by Roche in 2015. Dr. Stuelpnagel was the Chairman at Sequenta from 2010 until it was acquired by Adaptive where he remained a board member until 2017. In addition, he previously served as the Chairman of Element Biosciences from 2017 to 2023. 

Currently, Dr. Stuelpnagel is also the Chairman at 10x Genomics (since 2013) and Fabric Genomics). He is also a member of the board of directors for Encoded Therapeutics.

Dr. Stuelpnagel began his career as an associate at CW Group from 1997 to 1998.

He holds a doctorate in Veterinary Medicine and a bachelor’s degree in Biochemistry from the University of California, Davis, and an M.B.A. from the University of California, Los Angeles.